How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?  

Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk.  However, RA itself is considered a CV risk factor.  Therefore, it seems that all RA patients would potentially be excluded from JAKi therapy.  What risk factors should we really be using to determine CV risk?



Answer from: at Academic Institution
Comments
at Tristate Arthritis & Rheumatology
Thanks, Dr. @Jasvinder Singh! This approach is ver...
Sign in or Register to read more

Answer from: at Academic Institution